More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
ASCO 2024 – new matching strategy delays Caribou
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
ASCO 2024 preview – waiting for Blueprint and Caribou
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
ASH 2023 – a new EZ battle shapes up
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
